TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8024627
Drug: New tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet formulation of sotalol hydrochloride (80 mg)
Study: 8024627
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation of sotalol hydrochloride
Study: 28588165
Drug: Eptifibatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (10 mg intra coronary single bolus dose)
Study: 25921451
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa 2.5 mg/d via eRapid nebulizer
Study: 23406890
Drug: Talking Parents,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talking Parents, Healthy Teens program (8 weekly 1-hour sessions)
Study: 19589146
Drug: lafutidine 10
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lafutidine 10 mg with mosapride 5 mg
Study: 20084717
Drug: Fluoropyrimidine-based hepatic
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluoropyrimidine-based hepatic arterial infusion (HAI) chemotherapy
Study: 14995946
Drug: 7.5% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% NaCl infusion (4 ml kg‐1 over 10 min)
Study: 7997323
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir (400 mg 5 times daily, n = 51)
Study: 7997323
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir (400 mg 5 times daily)
Study: 29458932
Drug: Arsenicum album
Normalized name: Homeopathic Substance Oral Tablet [ARSENICUM ALBUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arsenicum album 30cH (6 doses, thrice daily for two days)
Study: 12971703
Drug: D-amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (10 mg every fourth day, totalling 100 mg in 36 days)
Study: 10702432
Drug: Modified left
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified left double-lumen tube (L-DLT)
Study: 28778219
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (TDB) patches starting at 5 μg/h, titrated to a maximum of 40 μg/h over 6 weeks, continued for 11 weeks.
Study: 26547914
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (TDB) patches
Study: 26684994
Drug: Immersive Visualization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive Visualization (IV) eyewear during oral debridement (Group A)
Study: 26684994
Drug: Immersive Visualization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive Visualization (IV) eyewear during oral debridement (Group B)
Study: 18334706
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with PELF (cisplatin 40 mg/m² on days 1 and 5, epirubicin 30 mg/m² on days 1 and 5, L-leucovorin 100 mg/m² on days 1-4, and 5-fluorouracil 300 mg/m² on days 1-4)
Study: 17190893
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg/d
Study: 10731626
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg iv)
Study: 10731626
Drug: MDMA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.5 mg/kg po)
Study: 3085428
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg diazepam orally
Study: 3085428
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam as a rectal solution
Study: 23313811
Drug: epratuzumab 2400
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epratuzumab 2400 mg cumulative dose (600 mg weekly)
Study: 23313811
Drug: epratuzumab 2400
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epratuzumab 2400 mg cumulative dose (1200 mg EOW)
Study: 23313811
Drug: epratuzumab 2400
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epratuzumab 2400 mg cumulative dose (all patients)
Study: 20024491
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo rFVIIa administration (45, 90, or 180 microg/kg)
Study: 20024491
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo rFVIIa spiking (0.6, 1.2, or 2.4 microg/ml)
Study: 20024491
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo rFVIIa administration
Study: 2045762
Drug: Felodipine ER,
Normalized name: Felodipine ER, 5 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER, 10 mg once daily for 2 weeks
Study: 2045762
Drug: Hydrochlorothiazide (HCTZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ), 25 mg once daily for 2 weeks
Study: 25986447
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg daily)
Study: 24867069
Drug: Arginine, glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplementation (twice per day for 16 weeks)
Study: 24867069
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink (twice per day for 16 weeks)
Study: 22942114
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment at 47 J/cm² (141 J/cm² total)
Study: 22942114
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment at 59 J/cm² (177 J/cm² total)
Study: 22942114
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment (all energy levels)
Study: 19127427
Drug: CC with
Normalized name: BD Syringe 5cc with Needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC with two doses rFSH
Study: 17202560
Drug: Methylphenidate (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (54 mg/day)
Study: 15609471
Drug: High-dose interleukin
Normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin (IL)-2 (Proleukin)
Study: 15609471
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy with IL-2 and interferon-alfa (biochemotherapy)
Study: 12562068
Drug: Proprioceptive neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive neuromuscular facilitation (PNF) training, 30 minutes daily for 10 treatments
Study: 12562068
Drug: Traditional training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional training, 30 minutes daily for 10 treatments
Study: 11475729
Drug: Capsule of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule of Prostatitis decoction
Study: 8580795
Drug: 400 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/m2/day etoposide
Study: 8580795
Drug: 600 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/m2/day etoposide
Study: 8580795
Drug: 200 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m2/day etoposide (control group)
Study: 2526769
Drug: Nicotinamide 3
Normalized name: PSATHYROTES RAMOSISSIMA WHOLE 36 g in 100 g / N-(HYDROXYMETHYL)NICOTINAMIDE 36 g in 100 g PERCUTANEOUS TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide 3 g/day for 9 months
Study: 359494
Drug: Cetiedil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetiedil (100 mg, t.i.d.)
Study: 359494
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 mg, t.i.d.)
Study: 359494
Drug: Orciprenaline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orciprenaline (20 mg, t.i.d.)
Study: 359494
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg Lactose, t.i.d.)
Study: 31905644
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) for eight weeks with a commercially available respiratory muscle trainer (Threshold IMT), 80 inhalations (twice per day, five days per week)
Study: 23220080
Drug: Niacinamide-containing formulations
Normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niacinamide-containing formulations applied twice daily for 28 days
Study: 21613278
Drug: Subcutaneous cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous cervical plexus block
Study: 9264494
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 to 480 mg/d
Study: 9264494
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 to 40 mg/d
Study: 3107444
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure ventilator for 3 to 6 hours daily for 3 consecutive days (Group B)
Study: 8083453
Drug: Methotrexate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15 mg weekly)
Study: 27320562
Drug: PCA fentanyl
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA fentanyl with IV parecoxib 40 mg
Study: 22651702
Drug: Bisoprolol dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol dose <5 mg
Study: 8843172
Drug: Gliclazide (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (240 mg orally)
Study: 1632534
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (ketorolac 60 mg IV and bupivacaine 0.5% 30 mL)
Study: 1632534
Drug: Bupivacaine (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.5% 30 mL)
Study: 30753540
Drug: POIBA intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: POIBA intervention (9-session classroom program, 6 weekly physical education sessions, out-of-school physical activity, family workshop)
Study: 27048410
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy for 8 weeks
Study: 27048410
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (budesonide nasal spray with cetirizine tablets for 8 weeks)
Study: 20682573
Drug: 1% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% plain subcutaneous lidocaine
Study: 17717933
Drug: Qishen Yiqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishen Yiqi Drop Pill
Study: 15640488
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (6 g green tea solids)
Study: 15640488
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (6 g black tea solids)
Study: 15640488
Drug: Control (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (360 mg caffeine)
Study: 7560667
Drug: Hydrocortisone sodium
Normalized name: Hydrocortisone Sodium Phosphate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone sodium succinate (100 mg administered intravenously)
Study: 7560667
Drug: Aspirin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (oral challenge)
Study: 2393271
Drug: Cefazolin (mean,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (mean, 178.6 mg/h)
Study: 2393271
Drug: Cefuroxime (mean,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (mean, 330.0 mg/h)
Study: 7015262
Drug: One-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day regimen of cefadroxil (30 mg/kg/day in two divided doses)
Study: 7015262
Drug: Ten-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten-day regimen of cefadroxil (30 mg/kg/day in two divided doses)
Study: 7015262
Drug: Short-term therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapy (one or four days of antibiotics)
Study: 7015262
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (ten-day regimen)
Study: 7015262
Drug: Short-term therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapy (all children in both studies)
Study: 7015262
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (all children in both studies)
Study: 30625184
Drug: Therapy dog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy dog exposure (15 min)
Study: 24908551
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitor with emtricitabine and tenofovir (no-switch group)
Study: 20977611
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants with immediate loading (group A)
Study: 19441871
Drug: Emtricitabine/tenofovir DF
Normalized name: COBICISTAT/ELVITEGRAVIR/EMTRICITABINE/TENOFOVIR DF TAB,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine/tenofovir DF 200 mg/300 mg once daily plus lopinavir/ritonavir
Study: 19441871
Drug: Emtricitabine/tenofovir DF
Normalized name: COBICISTAT/ELVITEGRAVIR/EMTRICITABINE/TENOFOVIR DF TAB,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine/tenofovir DF 200 mg/300 mg once daily
Study: 19441871
Drug: Emtricitabine/tenofovir DF
Normalized name: COBICISTAT/ELVITEGRAVIR/EMTRICITABINE/TENOFOVIR DF TAB,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine/tenofovir DF in combination with various boosted PIs
Study: 17497471
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once weekly (n = 47)
Study: 17497471
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once weekly (n = 44)
Study: 17497471
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg per day (n = 36)
Study: 11246837
Drug: Educational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational group (group E) with antihypertensive drug treatment and patient education
Study: 11246837
Drug: Routine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine group (group R) with antihypertensive drug treatment alone
Study: 7843814
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g administered intravenously within 1 h before surgery and a second dose 3-4 days postoperatively.
Study: 7843814
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic prophylaxis).
Study: 7843814
Drug: Ceftriaxone treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone treatment.
Study: 28628810
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration (starting dose 2μg/kg/d)
Study: 23648162
Drug: Low VT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low VT ventilation group (VT set on 6-7 ml/kg, high pressure alarm threshold adjusted to 60 cm H2O)
Study: 23648162
Drug: Conventional VT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional VT group (VT set at 8-12 ml/kg, high pressure alarm threshold at 40 cm H2O)
Study: 19107089
Drug: Back School
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back School program (4 weekly classes of 60 minutes)
Study: 15005771
Drug: Peanut flour
Normalized name: Peanut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut flour in mashed potatoes (2.7, 8.9, or 26.8 mg)
Study: 15005771
Drug: Hazelnut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelnut flour in oatmeal porridge (74, 247, or 742 mg)
Study: 8642803
Drug: Rilmenidine (RIL)
DrugBank: Rilmenidine (DB11738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (RIL) 1 mg o.d. or b.i.d.
Study: 8642803
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) 25 or 50 mg b.i.d.
Study: 2158355
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg once daily for 3 consecutive weeks
Study: 465434
Drug: B‐complex vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐complex vitamins (4 mg riboflavin and 10 mg pyridoxine) daily for 1 month
Study: 465434
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of gentian violet
Study: 465434
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin supplements
Study: 17431740
Drug: Randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment (specific intervention details not available)
Study: 9736546
Drug: Sparfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400 mg loading dose on day 1, then 200 mg once daily)
Study: 8527688
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg twice daily)
Study: 2620055
Drug: Dinoprostone pessary
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone pessary (3 mg)
Study: 29637896
Drug: Mg supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg supplementation
Study: 15009866
Drug: Flecainide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (2 mg/kg as a 30-minute IV infusion) before electrical cardioversion
Study: 15009866
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL IV infusion of 5% glucose) 30 minutes before electrical cardioversion
Study: 11587988
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone 500 microg twice daily
Study: 9861787
Drug: Model for
Normalized name: Model AA 2012 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model for identification and resolution of medication problems
Study: 7988630
Drug: Dihydrotachysterol preparations
Normalized name: Dihydrotachysterol
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotachysterol preparations (capsules and oral solution)
Study: 7988630
Drug: A.T.10 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: A.T.10 oral solution
Study: 29884231
Drug: Clonidine (75μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (75μg every 3rd hour up to a maximum of 4 doses, then 75μg twice daily until delirium free for 2 days, discharge or a maximum of 7 days)
Study: 25865041
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis started 24 hours pre intervention and for 5 days after
Study: 20961566
Drug: Daily nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nutritional supplementation for 6 months followed by daily GH therapy for 12 months
Study: 20961566
Drug: Observation for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation for 6 months followed by daily GH therapy for 12 months
Study: 30031369
Drug: Modified Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Cognitive Processing Therapy (SMART-CPT)
Study: 26707905
Drug: Low AMH
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low AMH (<1.00 ng/mL; n = 124)
Study: 26707905
Drug: Normal AMH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal AMH (1.00-3.5 ng/mL; n = 595)
Study: 26707905
Drug: High AMH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High AMH (>3.5 ng/mL; n = 483)
Study: 24372829
Drug: Metoclopramide nasal
Normalized name: metoclopramide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide nasal spray 20 mg
Study: 25576687
Drug: Metoclopramide nasal
Normalized name: metoclopramide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide nasal spray 10 mg
Study: 24372829
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide 10 mg
Study: 15920197
Drug: Conventional propofol-lidocaine
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional propofol-lidocaine mixtures with 20 mg lidocaine
Study: 15920197
Drug: Propofol-MCT/LCT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-MCT/LCT with 20 mg lidocaine
Study: 12727037
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release morphine sulfate (MSIR)
Study: 9366661
Drug: Assertive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive Community Treatment (ACT) program
Study: 1552711
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) therapy
Study: 1552711
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg orally) after baseline values
Study: 1552711
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg orally) after correction of hematocrit
Study: 29753637
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg administered orally once daily (with dose reductions to 40 mg or 20 mg for adverse events)
Study: 29753637
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg administered orally once daily
Study: 24237610
Drug: EP42675 (1-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP42675 (1-10 mg, single ascending doses)